Skip to main content

Table 3 Plasma thyroxine and TSH concentrations in the LT4-supplemented and placebo groups

From: An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks’ gestation: results of the TIPIT trial

 

TSH (mU/L)

FT4 (pmol/L)

 

LT4-supplemented

Placebo

P value

LT4-supplemented

Placebo

P value

Baseline

2.44 (1.06,4.03)

2.15 (1.27,3.40)

0.62a

12.24 (6.93)

10.53 (6.34)

0.18

n=43

n=53

 

n=53

n=54

Day 14

0.05 (0.01,0.14)

2.60 (1.60,4.00)

<0.001 a

20.17 (8.71)

12.01 (5.72)

<0.001

n=42

n=37

n=44

n=38

Day 21

0.06 (0.02,0.35)

2.29 (1.28, 2.76)

<0.001 a

20.89 (9.43)

12.02 (5.73)

<0.001

n=42

n=42

n=42

n=40

Day 28

0.12 (0.01,1.44)

4.0 (2.22. 6.20)

<0.001 a

16.18 (6.23)

11.42 (4.88)

0.005

n=38

n=35

n=38

n=36

Week 36

3.43 (1.82,4.90)

3.60 (2.10,4.70)

0.99a

14.44 (4.56)

16.76 (3.34)

0.009

n=39

n=39

n=44

n=43

  1. Data expressed as mean and standard deviation (SD) for continuous parametric outcomes and median and interquartile ranges (IQR) for non-parametric outcomes.
  2. Student t-test for analysis of continuous parametric outcomes.
  3. aMann-Whitney Wilcoxon test for non-parametric outcomes.